Payment overview · 2025
General Payments
$761.13
38 reported records · 14 companies
Healthcare provider profile · identity verified
Edward E Meier, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ROME, GA · NPI 1376537084
Verified facts
What the public records show
CMS Open Payments records show Edward E Meier, M.D. received $761.13 in general payments during 2025 across 38 reported records.
Astellas Pharma US Inc accounted for 18.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Nurtec Odt, Ozempic, Rybelsus, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $141.83 | 18.6% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $126.03 | 16.6% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $115.99 | 15.2% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $90.90 | 11.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $58.50 | 7.7% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.52 | 6.8% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $31.95 | 4.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.14 | 3.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.92 | 3.4% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $23.65 | 3.1% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.47 | 2.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.82 | 2.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.31 | 2.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.10 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $761.13 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $141.83 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $90.90 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $88.16 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $67.06 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $58.50 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $55.80 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $51.52 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $50.67 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $44.78 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $42.15 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $37.87 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $31.95 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.92 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 47 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 88 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 138 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 53 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
88 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
138 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
53 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
92 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 675 | 214 |
| Clonazepam | Clonazepam | 577 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 546 | 162 |
| Gabapentin | Gabapentin | 501 | 136 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 501 | 179 |
| Lisinopril | Lisinopril | 474 | 141 |
| Tramadol Hcl | Tramadol Hcl | 455 | 117 |
| Zolpidem Tartrate | Zolpidem Tartrate | 427 | 70 |
| Omeprazole | Omeprazole | 391 | 125 |
| Pantoprazole Sodium | Pantoprazole Sodium | 371 | 113 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 367 | 120 |
| Metformin Hcl | Metformin Hcl | 362 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 350 | 97 |
| Meloxicam | Meloxicam | 325 | 114 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 308 | 93 |
| Hydrochlorothiazide | Hydrochlorothiazide | 294 | 88 |
| Fluticasone Propionate | Fluticasone Propionate | 291 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 268 | 79 |
| Furosemide | Furosemide | 241 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 234 | 71 |
| Tizanidine Hcl | Tizanidine Hcl | 228 | 67 |
| Fenofibrate | Fenofibrate | 207 | 62 |
| Lorazepam | Lorazepam | 206 | 50 |
| Famotidine | Famotidine | 195 | 69 |
| Losartan Potassium | Losartan Potassium | 187 | 50 |
| Simvastatin | Simvastatin | 182 | 54 |
| Glipizide | Glipizide | 181 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 61 |
| Carvedilol | Carvedilol | 174 | 52 |
| Potassium Chloride | Potassium Chloride | 173 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 154 | 43 |
| Azithromycin | Azithromycin | 151 | 92 |
| Quetiapine Fumarate | Quetiapine Fumarate | 147 | 40 |
| Ezetimibe | Ezetimibe | 144 | 40 |
| Ozempic | Semaglutide | 138 | 25 |
| Alprazolam | Alprazolam | 137 | 18 |
| Celecoxib | Celecoxib | 136 | 52 |
| Diclofenac Sodium | Diclofenac Sodium | 132 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 41 |
| Ondansetron Odt | Ondansetron | 125 | 56 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 121 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 116 | 39 |
| Testosterone Cypionate | Testosterone Cypionate | 107 | 19 |
| Montelukast Sodium | Montelukast Sodium | 106 | 32 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 101 | 13 |
| Bupropion Xl | Bupropion Hcl | 99 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 99 | 27 |
| Trazodone Hcl | Trazodone Hcl | 99 | 27 |
| Pregabalin | Pregabalin | 98 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 97 | 28 |
| Eliquis | Apixaban | 92 | 24 |
| Mounjaro | Tirzepatide | 88 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 21 |
| Allopurinol | Allopurinol | 85 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 84 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 82 | 39 |
| Clonidine Hcl | Clonidine Hcl | 81 | 21 |
| Cefprozil | Cefprozil | 80 | 45 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 18 |
| Cephalexin | Cephalexin | 78 | 48 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 78 | 24 |
| Atenolol | Atenolol | 77 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 76 | 39 |
| Metformin Hcl Er | Metformin Hcl | 75 | 24 |
| Promethazine Hcl | Promethazine Hcl | 75 | 16 |
| Meclizine Hcl | Meclizine Hcl | 74 | 29 |
| Ibuprofen | Ibuprofen | 71 | 25 |
| Sertraline Hcl | Sertraline Hcl | 70 | 21 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 68 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 67 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 66 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 21 |
| Fluconazole | Fluconazole | 65 | 30 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 65 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 65 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 60 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 60 | 23 |
| Spironolactone | Spironolactone | 59 | 15 |
| Januvia | Sitagliptin Phosphate | 57 | 16 |
| Donepezil Hcl | Donepezil Hcl | 56 | 17 |
| Glipizide Er | Glipizide | 56 | 17 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 54 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 53 | 35 |
| Rybelsus | Semaglutide | 53 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 16 |
| Estradiol | Estradiol | 49 | 11 |
| Jardiance | Empagliflozin | 47 | 14 |
| Mupirocin | Mupirocin | 47 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | 17 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 43 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | suppressed |
| Methocarbamol | Methocarbamol | 40 | 11 |
| Methylprednisolone | Methylprednisolone | 39 | 27 |
| Naproxen | Naproxen | 39 | 14 |
| Temazepam | Temazepam | 39 | suppressed |
| Diazepam | Diazepam | 38 | suppressed |
| Eszopiclone | Eszopiclone | 38 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 37 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 15 |
| Varenicline Tartrate | Varenicline Tartrate | 36 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | suppressed |
| Nifedipine Er | Nifedipine | 34 | 11 |
| Propranolol Hcl | Propranolol Hcl | 34 | 12 |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 32 | 11 |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 28 | 14 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Ciclopirox | Ciclopirox | 25 | 11 |
| Colchicine | Colchicine | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 24 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 20 |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 14 |
| Amoxicillin | Amoxicillin | 19 | 13 |
| Glimepiride | Glimepiride | 19 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 19 | 12 |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Nystatin | Nystatin | 18 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Sucralfate | Sucralfate | 18 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 15 | suppressed |
| Mitigare | Colchicine | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Tretinoin | Tretinoin | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Indomethacin Er | Indomethacin | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Piroxicam | Piroxicam | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $761.13 · 38 records | Astellas Pharma US Inc | AREXVY, BREZTRI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, Dyanavel XR, GVOKE HYPOPEN, INSPIRE, JARDIANCE, Jornay PM, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, SAPIEN 3 Ultra RESILIA, SHINGRIX, TRELEGY ELLIPTA, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error